R&D at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s R&D?
- Edgewise Therapeutics, Inc. (EWTX) reported R&D of $42.65M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s R&D changed year-over-year?
- Edgewise Therapeutics, Inc.'s R&D increased by 16.0% year-over-year, from $36.76M to $42.65M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s R&D has grown at a 47.3% compound annual growth rate (CAGR), from $32.19M to $151.39M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.